Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nandrolone decanoate
Drug ID BADD_D01530
Description Nandrolone decanoate, also known as nandrolone caprinate, is an alkylated anabolic steroid indicated in the management of anemia of renal insufficiency and as an adjunct therapy in the treatment of senile and postmenopausal osteoporosis.[A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic effect compared to nandrolone and other esters.[A233849] Nandrolone decanoate was granted FDA approval on 5 October 1962.[L32564]
Indications and Usage Nandrolone decanoate is indicated in the management of anemia of renal insufficiency.[L32564] In Canada, it is also indicated as an adjunct therapy in the treatment of senile and postmenopausal osteoporosis.[L9464]
Marketing Status approved; illicit
ATC Code Not Available
DrugBank ID DB08804
KEGG ID D00955
MeSH ID D000077603
PubChem ID 9677
TTD Drug ID Not Available
NDC Product Code 60870-0233; 43647-123; 73774-013; 62991-2186; 51552-1564; 51927-0121; 22552-0048; 63275-9889
UNII H45187T098
Synonyms Nandrolone Decanoate | 17 beta-Hydroxyestr-4-en-3-one 17-decanoate | 17 beta Hydroxyestr 4 en 3 one 17 decanoate | 19-Nortestosterone Decanoate | 19 Nortestosterone Decanoate | 19-nor-4-Androstene-17 beta-ol-3-one 17-decanoate | 19 nor 4 Androstene 17 beta ol 3 one 17 decanoate | Retabolil | Retabolyl | Decadurabolin | Decadurobolin
Chemical Information
Molecular Formula C28H44O3
CAS Registry Number 360-70-3
SMILES CCCCCCCCCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertension24.08.02.001--
Hypertrophy08.03.04.005--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Irritability08.01.03.011; 19.04.02.013--
Jaundice09.01.01.004; 23.03.03.030; 01.06.04.004--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Libido increased21.03.02.007; 19.08.03.002--
Local reaction08.01.03.012--Not Available
Low density lipoprotein increased13.12.01.005--Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
Nausea07.01.07.001--
Oedema14.05.06.010; 08.01.07.006--Not Available
Oligomenorrhoea05.05.01.011; 21.01.02.004--Not Available
Oligospermia21.03.03.005--
Peliosis hepatis09.01.07.010--Not Available
Penis disorder21.12.01.001--Not Available
Priapism24.04.12.007; 21.03.01.005--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Seborrhoea23.02.07.001--Not Available
Seborrhoeic dermatitis23.03.04.018--Not Available
Sodium retention14.05.04.003--Not Available
Testicular atrophy21.13.01.001; 05.05.02.004--Not Available
Testicular failure21.13.01.004; 05.05.02.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Virilism21.10.04.001; 05.05.01.001--
Vomiting07.01.07.003--
Blood phosphorus increased13.11.01.016--Not Available
Drug tolerance08.06.01.003--Not Available
Haemorrhage24.07.01.002--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages